Predicting Recurrence After Radiotherapy in Head and Neck Cancer

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 108-118

  Begg, Adrian C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; MICRORNA; PROTEIN VP16;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL ASSAY; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LETHALITY; MOLECULARLY TARGETED THERAPY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84857553659     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.002     Document Type: Review

References (106)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Groome P.A., Schulze K., Boysen M., et al. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck 2001, 23:613-624.
3. Groome P.A., Schulze K., Boysen M., et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol 2002, 55:533-544.
4. Dubben H.H., Thames H.D., Beck-Bornholdt H.P. Tumor volume: A basic and specific response predictor in radiotherapy. Radiother Oncol 1998, 47:167-174.
5. Nathu R.M., Mancuso A.A., Zhu T.C., et al. The impact of primary tumor volume on local control for oropharyngeal squamous cell carcinoma treated with radiotherapy. Head Neck 2000, 22:1-5.
6. van den Broek G.B., Rasch C.R., Pameijer F.A., et al. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004, 101:1809-1817.
7. Björk-Eriksson T., West C., Karlsson E., et al. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 2000, 46:13-19.
8. Nordsmark M., Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000, 57:39-43.
9. Janssen H.L., Haustermans K.M., Balm A.J., et al. Hypoxia in head and neck cancer: How much, how important?. Head Neck 2005, 27:622-638.
10. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
11. Kim J.J., Tannock I.F. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005, 5:516-525.
12. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11:9-22.
13. Mazeron R., Tao Y., Lusinchi A., et al. Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncol 2009, 45:402-408.
14. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
15. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11:239-253.
16. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
17. Totoki Y., Tatsuno K., Yamamoto S., et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011, 43:464-469.
18. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
19. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
20. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
21. West C.M., Davidson S.E., Roberts S.A., et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993, 68:819-823.
22. Begg A.C. Predicting response to radiotherapy: Evolutions and revolutions. Int J Radiat Biol 2009, 85:825-836.
23. Kallioniemi A. CGH microarrays and cancer. Curr Opin Biotechnol 2008, 19:36-40.
24. Singh B., Kim S.H., Carew J.F., et al. Genome-wide screening for radiation response factors in head and neck cancer. Laryngoscope 2000, 110:1251-1256.
25. van den Broek G.B., Wreesmann V.B., Van den Brekel M.W., et al. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clin Cancer Res 2007, 13:4386-4391.
26. Olive P.L. Retention of gammaH2AX foci as an indication of lethal DNA damage. Radiother Oncol 2011, 101:18-23.
27. Olive P.L., Banuelos C.A., Durand R.E., et al. Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix. Radiother Oncol 2010, 94:82-89.
28. Menegakis A., Eicheler W., Yaromina A., et al. Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol 2011, 100:137-144.
29. Torres-Roca J.F., Eschrich S., Zhao H., et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005, 65:7169-7176.
30. Amundson S.A., Do K.T., Vinikoor L.C., et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008, 68:415-424.
31. Pramana J., Van den Brekel M.W., van Velthuysen M.L., et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:1544-1552.
32. Eschrich S.A., Pramana J., Zhang H., et al. A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009, 75:489-496.
33. de Jong M.C., Pramana J., van der Wal J.E., et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010, 16:5329-5338.
34. Hennessey P.T., Ochs M.F., Mydlarz W.W., et al. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS ONE 2011, 6:e20584.
35. Höckel M., Knoop C., Schlenger K., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26:45-50.
36. Vaupel P., Kelleher D.K., Hockel M. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28:29-35.
37. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
38. Cairns R.A., Hill R.P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004, 64:2054-2061.
39. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38:285-289.
40. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47.
41. Fardin P., Cornero A., Barla A., et al. Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-L2 regularization and data reduction. J Biomed Biotechnol 2010, 2010:878709.
42. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67:3441-3449.
43. Jeong S.H., Wu H.G., Park W.Y. LIN28B confers radio-resistance through the posttranscriptional control of KRAS. Exp Mol Med 2009, 41:912-918.
44. Oh J.S., Kim J.J., Byun J.Y., et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010, 76:5-8.
45. Chun-Zhi Z., Lei H., An-Ling Z., et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010, 10:367.
46. Farazi T.A., Spitzer J.I., Morozov P., et al. miRNAs in human cancer. J Pathol 2011, 223:102-115.
47. Gee H.E., Camps C., Buffa F.M., et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116:2148-2158.
48. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
49. Bussink J., Kaanders J.H., van der Kogel A.J. Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15.
50. Janssen H.L., Haustermans K.M., Sprong D., et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002, 54:1537-1549.
51. Eriksen J.G., Overgaard J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiother Oncol 2007, 83:383-388. Danish Head and Neck Cancer Study Group (DAHANCA).
52. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocols 5-85. Radiother Oncol 1998, 46:135-146.
53. De S.H., Landuyt W., Verbeken E., et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005, 5:42.
54. Calvin D.P., Hammond M.E., Pajak T.F., et al. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: Results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol 2007, 30:406-419.
55. Baujat B., Bourhis J., Blanchard P., et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010, CD002026.
56. Begg A.C., Haustermans K., Hart A.A., et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiother Oncol 1999, 50:13-23.
57. Couture C., Raybaud-Diogène H., Têtu B., et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002, 94:713-722.
58. Kropveld A., Slootweg P.J., Blankenstein M.A., et al. Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope 1998, 108:1548-1552.
59. Raybaud H., Fortin A., Bairati I., et al. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg 2000, 29:36-41.
60. Eriksen J.G., Steiniche T., Overgaard J., et al. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol 2005, 44:50-58.
61. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005, 23:5560-5567.
62. Buffa F.M., Bentzen S.M., Daley F.M., et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004, 10:3745-3754.
63. Starmans M.H., Krishnapuram B., Steck H., et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008, 99:1884-1890.
64. Starmans M.H., Zips D., Wouters B.G., et al. The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiother Oncol 2009, 92:417-422.
65. Kim I.A., Bae S.S., Fernandes A., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005, 65:7902-7910.
66. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 2002, 8:885-892.
67. Massarelli E., Liu D.D., Lee J.J., et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005, 104:2430-2436.
68. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
69. Chung C.H., Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-4176.
70. Harari P.M., Wheeler D.L., Grandis J.R. Molecular target approaches in head and neck cancer: Epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009, 19:63-68.
71. Ragin C.C., Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer 2007, 121:1813-1820.
72. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1992-1998.
73. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
74. Robinson M., Sloan P., Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010, 46:492-496.
75. Slebos R.J., Yi Y., Ely K., et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:701-709.
76. Lohavanichbutr P., Houck J., Fan W., et al. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: Potential implications for treatment choices. Arch Otolaryngol Head Neck Surg 2009, 135:180-188.
77. de Jong M.C., Pramana J., Knegjens J.L., et al. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol 2010, 95:365-370.
78. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010, 94:30-35.
79. Brockton N., Dort J., Lau H., et al. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011, 80:249-257.
80. Clarke M.F., Dick J.E., Dirks P.B., et al. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
81. Baumann M., Krause M., Thames H., et al. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009, 85:391-402.
82. Hill R.P., Marie-Egyptienne D.T., Hedley D.W. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009, 19:106-111.
83. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-1521.
84. Wu M.J., Jan C.I., Tsay Y.G., et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer 2010, 9:283. 283.
85. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
86. Sabbah M., Emami S., Redeuilh G., et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Update 2008, 11:123-151.
87. Chung C.H., Parker J.S., Ely K., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006, 66:8210-8218.
88. Theys J., Jutten B., Habets R., et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol 2011, 99:392-397.
89. Marsit C.J., Posner M.R., McClean M.D., et al. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 2008, 113:1566-1571.
90. Fong P.C., Yap T.A., Boss D.S., et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
91. Veeck J., Ropero S., Setien F., et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010, 28:e563-e564.
92. Joosse S.A., van Beers E.H., Tielen I.H., et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 2009, 116:479-489.
93. Willers H., Taghian A.G., Luo C.M., et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309.
94. Smith I.M., Mithani S.K., Mydlarz W.K., et al. Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. ORL J Otorhinolaryngol Relat Spec 2010, 72:44-50.
95. Szaumkessel M., Richter J., Giefing M., et al. Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma. Int J Oncol 2011, 39:505-514.
96. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO. Mol Med 2009, 1:315-322.
97. Vens C., Begg A.C. Targeting base excision repair as a sensitization strategy in radiotherapy. Semin Radiat Oncol 2010, 20:241-249.
98. Neijenhuis S., Verwijs-Janssen M., van den Broek L.J., et al. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res 2010, 70:8706-8714.
99. Verheij M., Vens C., van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010, 13:29-43.
100. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011, 10:351-364.
101. Wreesmann V.B., Shi W., Thaler H.T., et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004, 22:3965-3972.
102. Gibcus J.H., Mastik M.F., Menkema L., et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer 2008, 98:950-955.
103. Rodrigo J.P., García-Carracedo D., García L.A., et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 2009, 217:516-523.
104. Timpson P., Lynch D.K., Schramek D., et al. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 2005, 65:3273-3280.
105. de Koning P.J., Bovenschen N., Leusink F.K., et al. Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome. Int J Cancer 2009, 125:1542-1550.
106. Shellenberger T.D., Mazumdar A., Henderson Y., et al. Headpin: A serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 2005, 65:11501-11509.